In preclinical models, class I HDAC and BET-inhibitors (discussed below) showed synergistic anti-tumor effects against pancreatic cancer through the dysregulation of FOSL-1 [48]. This evidence concerns the gene HDAC9 and familial pancreatic carcinoma.